Mkts

Immunome, Inc.

NASDAQ: IMNM
$18.77+0.07 (+0.37%)
As of Nov 13, 4:00 PM ET

Key statistics

Day range
18.1018.92
52-week range
16.1130.06
Today
Open18.62
Previous close18.77
Volume1.31M
Valuation
Market cap2.22B
P/E ratio—
EPS (TTM)-2.61
Income & risk
Dividend / yield—
Beta2.80
Avg volume1.28M
Discussion

IMNM News

Stories mentioning IMNM from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue0.000.000.004,0152,9262,7382,9102,364
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development46,38150,77049,19340,45136,87247,89037,20029,083
Sales General & Admin
Total Operating Expenses59,33172,86160,13850,49347,56285,70853,43242,373
Operating Income (Loss)(59,331)(72,861)(60,138)(46,478)(44,636)(82,970)(50,522)(40,009)
Interest Income
Interest Expense
Other Expense
Pretax Income
Tax Provision
Net Income (Loss)(53,839)(69,900)(57,457)(43,397)(41,640)(80,249)(47,100)(36,122)
Earnings Per Share (Basic)(0.48)(0.80)(0.65)(0.50)(0.52)(1.37)(0.78)(0.60)
Earnings Per Share (Diluted)(0.48)(0.80)(0.65)(0.50)(0.52)(1.37)(0.78)(0.60)
Weighted Average Shares Outstanding (Basic)113,13787,35187,95887,01179,41058,63960,20559,937
Weighted Average Shares Outstanding (Diluted)113,13787,35187,95887,01179,41058,63960,20559,937

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About IMNM

Immunome, Inc. (NASDAQ: IMNM) is a stock listed on the Nasdaq Stock Market under the ticker symbol IMNM. It last traded at $18.77 (Nov 13, 2026, 4:00 PM ET), up 0.4% on the day. That gives Immunome a market capitalisation of $2.2B.

Over the past 52 weeks IMNM has traded between $16.11 and $30.06.

Revenue for the quarter ended Mar 31, 2026 was $0; a net loss of $53.8M.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$0-$53.8M—
Dec 31, 2025$0-$69.9M—
Sep 30, 2025$0-$57.5M—
Jun 30, 2025$4.0M-$43.4M-1080.9%

From Immunome’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…